Shanxi Zhendong Pharmaceutical Co.,Ltd (SHE:300158)
China · Delayed Price · Currency is CNY 5.59
-0.11 (-1.93%)
May 20, 2026, 1:45 PM CST
SHE:300158 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,655 | 2,760 | 2,948 | 3,607 | 3,665 | 5,028 |
Other Revenue | 23.13 | 23.13 | 23.6 | 19.37 | 63.98 | 66.1 |
| 2,678 | 2,783 | 2,971 | 3,626 | 3,729 | 5,094 | |
Revenue Growth (YoY) | -9.03% | -6.33% | -18.06% | -2.75% | -26.80% | 5.07% |
Cost of Revenue | 1,306 | 1,389 | 1,812 | 1,830 | 1,894 | 2,058 |
Gross Profit | 1,372 | 1,394 | 1,159 | 1,796 | 1,834 | 3,036 |
Selling, General & Admin | 1,492 | 1,507 | 1,441 | 1,762 | 1,808 | 2,662 |
Research & Development | 176.97 | 179.93 | 349.79 | 189.43 | 178.11 | 218.73 |
Other Operating Expenses | 6.28 | 5.01 | 7.79 | -34.98 | -22.64 | 15.01 |
Operating Expenses | 1,681 | 1,697 | 1,793 | 1,896 | 1,949 | 2,887 |
Operating Income | -308.65 | -303.32 | -634.14 | -99.52 | -114.52 | 148.84 |
Interest Expense | -2.75 | -2.21 | -3.9 | -1.21 | -13.78 | -19.63 |
Interest & Investment Income | 8.33 | 12.1 | 47.64 | 54.67 | 60.7 | 2,959 |
Currency Exchange Gain (Loss) | -0.18 | -0.18 | -0.13 | 0 | 0 | - |
Other Non Operating Income (Expenses) | 4.92 | -0.93 | -2.55 | -11.07 | 28.7 | -20.72 |
EBT Excluding Unusual Items | -298.32 | -294.54 | -593.08 | -57.12 | -38.9 | 3,068 |
Impairment of Goodwill | - | - | -24.74 | - | - | -0.49 |
Gain (Loss) on Sale of Investments | 1.38 | 1.59 | -139.44 | 1.96 | 11.59 | 0.83 |
Gain (Loss) on Sale of Assets | -0.71 | -0.78 | 10.54 | 0 | -0.86 | -0.49 |
Asset Writedown | -10.26 | - | -18.77 | -7.62 | -0.94 | -13.15 |
Other Unusual Items | 26.61 | 16.11 | -549.54 | 25.09 | 23.84 | 61.62 |
Pretax Income | -281.29 | -277.62 | -1,315 | -37.69 | -5.28 | 3,116 |
Income Tax Expense | 23.99 | 25.46 | 17.92 | 10.18 | 51.72 | 506.49 |
Earnings From Continuing Operations | -305.28 | -303.09 | -1,333 | -47.87 | -57 | 2,610 |
Minority Interest in Earnings | 2.02 | 2.02 | 4.38 | 3.89 | 5.71 | 7.8 |
Net Income | -303.26 | -301.06 | -1,329 | -43.98 | -51.29 | 2,617 |
Net Income to Common | -303.26 | -301.06 | -1,329 | -43.98 | -51.29 | 2,617 |
Net Income Growth | - | - | - | - | - | 898.92% |
Shares Outstanding (Basic) | 1,001 | 1,004 | 1,024 | 1,028 | 1,028 | 1,027 |
Shares Outstanding (Diluted) | 1,001 | 1,004 | 1,024 | 1,028 | 1,028 | 1,027 |
Shares Change (YoY) | -0.73% | -1.91% | -0.38% | -0.02% | 0.04% | -0.01% |
EPS (Basic) | -0.30 | -0.30 | -1.30 | -0.04 | -0.05 | 2.55 |
EPS (Diluted) | -0.30 | -0.30 | -1.30 | -0.04 | -0.05 | 2.55 |
EPS Growth | - | - | - | - | - | 898.98% |
Free Cash Flow | -606.64 | -639.6 | -448.3 | -365.39 | -64.49 | 132.79 |
Free Cash Flow Per Share | -0.61 | -0.64 | -0.44 | -0.36 | -0.06 | 0.13 |
Dividend Per Share | - | - | - | - | - | 2.800 |
Dividend Growth | - | - | - | - | - | 3900.00% |
Gross Margin | 51.24% | 50.08% | 39.00% | 49.54% | 49.20% | 59.60% |
Operating Margin | -11.53% | -10.90% | -21.34% | -2.74% | -3.07% | 2.92% |
Profit Margin | -11.33% | -10.82% | -44.72% | -1.21% | -1.38% | 51.39% |
Free Cash Flow Margin | -22.66% | -22.98% | -15.09% | -10.08% | -1.73% | 2.61% |
EBITDA | -194.6 | -189.37 | -520.57 | 22.15 | 11.49 | 273.97 |
EBITDA Margin | -7.27% | -6.80% | -17.52% | 0.61% | 0.31% | 5.38% |
D&A For EBITDA | 114.04 | 113.95 | 113.57 | 121.68 | 126.01 | 125.13 |
EBIT | -308.65 | -303.32 | -634.14 | -99.52 | -114.52 | 148.84 |
EBIT Margin | -11.53% | -10.90% | -21.34% | -2.74% | -3.07% | 2.92% |
Effective Tax Rate | - | - | - | - | - | 16.25% |
Revenue as Reported | 2,678 | 2,783 | 2,971 | 3,626 | 3,729 | 5,094 |
Advertising Expenses | - | 3.18 | - | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.